BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12485499)

  • 21. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
    Martín J; Poveda A; Llombart-Bosch A; Ramos R; López-Guerrero JA; García del Muro J; Maurel J; Calabuig S; Gutierrez A; González de Sande JL; Martínez J; De Juan A; Laínez N; Losa F; Alija V; Escudero P; Casado A; García P; Blanco R; Buesa JM;
    J Clin Oncol; 2005 Sep; 23(25):6190-8. PubMed ID: 16135486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
    Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
    Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telomerase activity as prognostic factor in gastrointestinal stromal tumors of the stomach.
    Kawai J; Kodera Y; Fujiwara M; Kasai Y; Nagasaka T; Koike M; Hibi K; Ito K; Akiyama S; Nakao A
    Hepatogastroenterology; 2005; 52(63):959-64. PubMed ID: 15966241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site.
    Antonescu CR; Viale A; Sarran L; Tschernyavsky SJ; Gonen M; Segal NH; Maki RG; Socci ND; DeMatteo RP; Besmer P
    Clin Cancer Res; 2004 May; 10(10):3282-90. PubMed ID: 15161681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors.
    Motegi A; Sakurai S; Nakayama H; Sano T; Oyama T; Nakajima T
    Pathol Int; 2005 Mar; 55(3):106-12. PubMed ID: 15743318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An immunohistochemical and molecular study of gastrointestinal stromal tumours.
    Teong YT; Teo ST; Tan LP; Wu BQ; Peh SC
    Med J Malaysia; 2006 Dec; 61(5):526-33. PubMed ID: 17623951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients.
    Kinoshita K; Hirota S; Isozaki K; Ohashi A; Nishida T; Kitamura Y; Shinomura Y; Matsuzawa Y
    J Pathol; 2004 Jan; 202(1):80-5. PubMed ID: 14694524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemistry and c-kit gene analysis in determining malignancy in gastrointestinal stromal tumors.
    Yamaguchi M; Tate G; Endo Y; Miyaki M
    Hepatogastroenterology; 2003; 50(53):1431-5. PubMed ID: 14571755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations.
    Kang HJ; Koh KH; Yang E; You KT; Kim HJ; Paik YK; Kim H
    Proteomics; 2006 Feb; 6(4):1151-7. PubMed ID: 16402362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.
    Boldrini L; Ursino S; Gisfredi S; Faviana P; Donati V; Camacci T; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4101-8. PubMed ID: 15217946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
    Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract.
    Hirota S; Isozaki K; Nishida T; Kitamura Y
    J Gastroenterol; 2000; 35 Suppl 12():75-9. PubMed ID: 10779223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.
    Choi YR; Kim H; Kang HJ; Kim NG; Kim JJ; Park KS; Paik YK; Kim HO; Kim H
    Cancer Res; 2003 May; 63(9):2188-93. PubMed ID: 12727838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial gastrointestinal stromal tumors caused by the novel KIT exon 17 germline mutation N822Y.
    Thalheimer A; Schlemmer M; Bueter M; Merkelbach-Bruse S; Schildhaus HU; Buettner R; Hartung E; Thiede A; Meyer D; Fein M; Maroske J; Wardelmann E
    Am J Surg Pathol; 2008 Oct; 32(10):1560-5. PubMed ID: 18724244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course.
    Lasota J; Dansonka-Mieszkowska A; Stachura T; Schneider-Stock R; Kallajoki M; Steigen SE; Sarlomo-Rikala M; Boltze C; Kordek R; Roessner A; Stachura J; Miettinen M
    Mod Pathol; 2003 Dec; 16(12):1257-64. PubMed ID: 14681327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.